Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AC Immune (ACIU) shares

Learn how to easily invest in AC Immune shares.

AC Immune is a biotechnology business based in the US. AC Immune stocks (ACIU.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.92 – a decrease of 7.47% over the previous week. AC Immune employs 125 staff and has a trailing 12-month revenue of around $944,000.

How to buy shares in AC Immune

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACIU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AC Immune stock price (NASDAQ:ACIU)

Use our graph to track the performance of ACIU stocks over time.

AC Immune shares at a glance

Information last updated 2022-01-17.
Latest market close$4.46
52-week range$4.58 - $12.50
50-day moving average $5.34
200-day moving average $6.53
Wall St. target price$14.39
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.08

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy AC Immune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AC Immune price performance over time

Historical closes compared with the close of $4.46 from 2022-01-20

1 week (2022-01-14) -7.47%
1 month (2021-12-21) -13.06%
3 months (2021-10-21) -26.16%
6 months (2021-07-21) -41.32%
1 year (2021-01-21) -26.04%
2 years (2020-01-21) -52.80%
3 years (2019-01-18) 11.34
5 years (2017-01-20) 12.6

AC Immune financials

Revenue TTM $944,000
Gross profit TTM $-44,056,000
Return on assets TTM -20.37%
Return on equity TTM -34.53%
Profit margin 0%
Book value $2.46
Market capitalisation $350.2 million

TTM: trailing 12 months

AC Immune share dividends

We're not expecting AC Immune to pay a dividend over the next 12 months.

AC Immune share price volatility

Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.58 up to $12.5. A popular way to gauge a stock's volatility is its "beta".

ACIU.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.817. This would suggest that AC Immune's shares are less volatile than average (for this exchange).

AC Immune overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site